Dr. John Cush RheumNow
5 years 4 months ago
RNL 2021 - Spondyloarthritis Q & A Panel Discussion
https://t.co/3oFZNV0XI6
Dr. John Cush RheumNow
5 years 4 months ago
New podcast available— BandAids for Rheumatologists. Listen on SoundCloud and wherever podcasts are available.
https://t.co/AGROPnfAAi
Dr. John Cush RheumNow
5 years 4 months ago
RNL 2021: EULAR 2019 and ACR 2020 RA Treatment Guidelines - Dr. Alan Matsumoto
Dr. Alan Matsumoto presents EULAR 2019 and ACR 2020 RA Treatment Guidelines at the 2021 RheumNow Live meeting.
https://t.co/1swZIWGWKc
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.
We love Rheumatology!
Dr. John Cush RheumNow
5 years 4 months ago
Cerecor has launched a c Phase 1b clinical trial (NCT04752371) of the human mAb CERC-007, targeting IL-18, in 12 patients with active adult onset Still’s disease (AOSD). They estimate AOSD affects 3,500 - 7,000 in the US 3,400 - 6,900 pts in Europe https://t.co/DlW1QbXOG0
Dr. John Cush RheumNow
5 years 4 months ago
CDC study from 33 sites, 25 states showed vaccine efficacy (against Sx COVID) in HCP was 82% with ONEdose (Pfizer, Moderna) and 94% for TWO doses (same as RCTs). The efficacy of only 1 dose (of a 2 dose COVID vax) is likely to be 70- 82%. https://t.co/uQhUmjSsRd
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
RNL has finished its 3rd year as a hybrid meeting, with the live meeting streamed to hundreds at home, who are watching and interacting on the same content viewed by those in attendance in Fort Worth.
Dr. John Cush RheumNow
5 years 4 months ago
Dr. Mike Putman - TULIP Trials - Anifrolumab in SLE
https://t.co/cqZiulDMFm
#LupusAwarenessMonth https://t.co/kNKLUSOKWp
Dr. John Cush RheumNow
5 years 4 months ago
Clinical practice data study of 855 Psoriatic arthritis patients. With no differences in treatment, women has worse disease activity score (vs M) (PASDAS 3.5 vs 2.7; p < 0.001). Higher BMI assoc w/ no reaching Low Dz activity in Women, not men. https://t.co/CVAEHhjqCH
Dr. John Cush RheumNow
5 years 4 months ago
Worth sharing again-- ACR Updates COVID-19 Vaccine Guidance- April 2021
The ACR COVID-19 Vaccine Clinical Guidance was originally published on 2/8/21 & updated on 3/4/21. On 4/28/21, new recommendations were added.
https://t.co/BgrFxCgjRw https://t.co/O7ngEBEX6s
The U.S. Centers for Disease Control and Prevention (CDC) today updated COVID guidance such that fully vaccinated people do not need to wear masks outdoors, can avoid wearing them indoors in most places, and in most places will not need to physically distance. CDC believes these changes will encourage more Americans to get vaccinated.
Dr. John Cush RheumNow
5 years 4 months ago
Johns Hopkins researchers suggest that treating refractory dermatomyositis with a JAK inhibitor may improve calcinosis. Based on 3 case reports, who had either NXP2 or TIF-1γ refractory DM, all improved their skin, muscle dz and calcinosis. https://t.co/P5k5y0HS6A
Dr. John Cush RheumNow
5 years 4 months ago
News Feature: Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease
https://t.co/ps8JeRUtJf https://t.co/Sn6ykG9ZuE
Dr. John Cush RheumNow
5 years 4 months ago
Sulfasalazine may be in short supply. FDA shortage lists shortage with drug return in July or 4th quarter of 2021. ASHP site also notes several generic maker shortages but they suggest resolution mid-May or July https://t.co/XYyraO6Z4z https://t.co/tm50S7ov9K https://t.co/QPWIitYkpp
